Edgewise Therapeutics, Inc., (NASDAQ: EWTX), is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.
Location: United States, Colorado, Boulder
Employees: 11-50
Phone: +1 720-262-7002
Total raised: $145M
Founded date: 2017
Investors 5
| Date | Name | Website |
| 20.02.2021 | Logos Capi... | logoscapit... |
| - | US Venture... | usvp.com |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.12.2020 | Series C | $95M | - |
| 17.09.2019 | Series B | $50M | - |
Mentions in press and media 13
| Date | Title | Description | Source |
| 17.04.2024 | Parent Project Muscular Dystrophy Celebrates 30th Anniversar... | PPMD Together: Cincinnati Marks Three Decades of PPMD's Impact and Mayor's Proclamation Honors Found... | salamancap... |
| 04.12.2023 | Business | FDA grants orphan status to Edgewise’s muscular d... | BOULDER — The U.S. Food and Drug Administration has granted Orphan Drug Designation for a drug produ... | dailycamer... |
| 31.03.2021 | Edgewise Therapeutics closes out surprise IPO with $202.4M r... | Edgewise Therapeutics Inc. (Nasdaq: EWTX) raised $202.4 million in funding from its confidentially f... | dailycamer... |
| 26.03.2021 | Edgewise Therapeutics reveals $176M IPO plan after confident... | Edgewise Therapeutics Inc. (Nasdaq: EWTX) kicked off its initial public offering Friday morning, mar... | dailycamer... |
| 15.12.2020 | Biopharmaceutical Company Edgewise Therapeutics Closes $95 M... | Edgewise Therapeutics recently announced the closing of a $95 million Series C preferred stock finan... | pulse2.com... |
| 09.12.2020 | Boulder’s Edgewise Therapeutics raises $95M to fund muscular... | Edgewise Therapeutics Inc. has more than doubled its previous fundraising rounds by closing a $95 mi... | dailycamer... |
| 08.12.2020 | Edgewise Therapeutics Completes $95 Million Series C Financi... | - | orbimed.co... |
| 08.12.2020 | Edgewise Therapeutics Completes $95 Million Series C Financi... | - | usvp.com/n... |
| 17.09.2019 | Boulder’s Edgewise Therapeutics closes $50 million Series B ... | Edgewise Therapeutics, a Boulder company working to develop new therapies for treating patients with... | dailycamer... |
| 17.09.2019 | Edgewise Therapeutics Raises $50M in Series B Financing | Edgewise Therapeutics, a Boulder, Colo.-based preclinical company developing small molecule therapie... | finsmes.co... |
Show more